Strategic partnerships PharmaJet is actively pursuing collaborations with global health networks and regional partners (AFENET, EVA Pharma, Egyptian UPA) to deploy needle-free Tropis systems and expand immunization programs, signaling strong channel and co-marketing opportunities for distributors and integrators.

Product expansion The company is broadening its needle-free offerings with self-injector pens and pens for self-administration in chronic disease markets, presenting cross-sell potential to healthcare providers, payers, and patient support programs seeking comfort-friendly delivery options.

Regulatory readiness With FDA 510(k) clearance, CE Mark, and WHO PQS certifications for its Stratis and Tropis systems, PharmaJet has global market access advantages that can be leveraged to secure new tenders, immunization programs, and international sponsorships.

Public health focus A clear emphasis on immunization effectiveness, patient/caregiver experience, and public health impact positions the company well for government contracts, NGO programs, and donor-funded immunization initiatives in emerging markets.

Financial and scale signals Despite a lean company size, PharmaJet has meaningful funding and revenue potential, suggesting readiness for pilot programs, scaled deployments, and multi-country contracts with OEMs, integrators, and global health entities.